Literature DB >> 10201931

Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor.

N Nagvekar1, L Corlett, L W Jacobson, H Matsuo, R Chalkley, P C Driscoll, S Deshpande, E G Spack, N Willcox.   

Abstract

A recurring epitope in the human acetylcholine receptor (AChR) alpha subunit (alpha146-160) is presented to specific T cells from myasthenia gravis patients by HLA-DRB3*0101-"DR52a"-or by DR4. Here we first map residues critical for DR52a in this epitope by serial Ala substitution. For two somewhat similar T cells, this confirms the recently deduced importance of hydrophobic "anchor" residues at peptide p1 and p9; also of Asp at p4, which complements this allele's distinctive Arg74 in DRbeta. Surprisingly, despite the 9 sequence differences in DRbeta between DR52a and DR3, merely reducing the bulk of the peptide's p1 anchor residue (Trp149-->Phe) allowed maximal cross-presentation to both T cells by DR3 (which has Val86 instead of Gly). The shared K71G73R74N77 motif in the alpha helices of DR52a and DR3 thus outweighs the five differences in the floor of the peptide-binding groove. A second issue is that T cells selected in vitro with synthetic AChR peptides rarely respond to longer Ag preparations, whereas those raised with recombinant subunits consistently recognize epitopes processed naturally even from whole AChR. Here we compared one T cell of each kind, which both respond to many overlapping alpha140-160 region peptides (in proliferation assays). Even though both use Vbeta2 to recognize peptides bound to the same HLA-DR52a in the same register, the peptide-selected line nevertheless proved to depend on a recurring synthetic artifact-a widely underestimated problem. Unlike these contaminant-responsive T cells, those that are truly specific for natural AChR epitopes appear less heterogeneous and therefore more suitable targets for selective immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201931

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Shared αβ TCR Usage in Lungs of Sarcoidosis Patients with Löfgren's Syndrome.

Authors:  Angela M Mitchell; Ylva Kaiser; Michael T Falta; Daniel J Munson; Laurie G Landry; Anders Eklund; Maki Nakayama; Jill E Slansky; Johan Grunewald; Andrew P Fontenot
Journal:  J Immunol       Date:  2017-08-21       Impact factor: 5.422

2.  Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.

Authors:  M Peakman; E J Stevens; T Lohmann; P Narendran; J Dromey; A Alexander; A J Tomlinson; M Trucco; J C Gorga; R M Chicz
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

3.  Lung restricted T cell receptor AV2S3+ CD4+ T cell expansions in sarcoidosis patients with a shared HLA-DRbeta chain conformation.

Authors:  J Grunewald; J Wahlström; M Berlin; H Wigzell; A Eklund; O Olerup
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

4.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

Review 5.  Role of CD4+ T cells in sarcoidosis.

Authors:  Johan Grunewald; Anders Eklund
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

Review 6.  Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society.

Authors:  R Mallone; S I Mannering; B M Brooks-Worrell; I Durinovic-Belló; C M Cilio; F S Wong; N C Schloot
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

7.  John Newsom-Davis: clinician-scientist and so much more.

Authors:  Angela Vincent
Journal:  Brain       Date:  2011-12       Impact factor: 13.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.